logo-loader
viewRhinomed Ltd

Rhinomed Limited to advance distribution of snoring product

au_medical_350_5518aa6159b51.jpg

Rhinomed Limited (ASX:RNO) has been granted an ASX trading halt in relation to the appointment of an Australian Pharmacy Distribution group for its Mute over-the-counter snoring product.
   
The halt will last until the earlier of the announcement being made or the start of trade on Wednesday, 1st April 2015.

Independent user trial results (conducted November 2014) confirmed the efficacy of Mute with 75% of respondents reported a reduction in snoring.



Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

Quick facts: Rhinomed Ltd

Price: 0.07 AUD

ASX:RNO
Market: ASX
Market Cap: $11.84 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Fax Capital CEO talks investment and aligning with the right...

Fax Capital (TSE: FXC-) CEO Blair Driscoll joined Steve Darling from Proactive Vancouver to discuss the investment holding company that intends to invest in approximately 10 to 15 high-quality small-cap public and private businesses located primarily in Canada. Driscoll tells Proactive why...

1 hour, 31 minutes ago

2 min read